<DOC>
	<DOCNO>NCT01926054</DOCNO>
	<brief_summary>This open-label , randomize , multi-center , Phase IV study Acthar Gel patient biopsy-proven membranous ( Class V ) lupus nephritis ( LN ) aim provide proof-of-concept data Acthar safe effective therapy membranous LN . Class V LN secondary form membranous nephropathy , occur 8-20 % patient LN . Two different dos Acthar Gel test . The active intervention phase study take place 6 month , follow-up occur follow 6 month . Efficacy safety use Acthar Gel treatment membranous LN assess analyze throughout course study laboratory testing , physical exam , evaluation tool . Subjects closely monitor adverse effect associate use Acthar gel necessary study drug dose reduce . The anticipated benefit subject complete renal response rate 40 % 6 month show superiority publish complete remission rate currently use immunosuppressive therapy , unexpected toxicity signal . Pure Class V LN affect significant number systemic lupus erythematosus ( SLE ) patient although less aggressive proliferative form LN still cause important renal non-renal morbidity mortality time , especially patient remain nephrotic . The therapy Class V LN clear , currently use therapy highly toxic immunosuppression , risk infertility , risk future malignancy . Additionally , therapy modestly effective induce remission Class V LN . There thus unmet need effective less toxic treatment Class V LN .</brief_summary>
	<brief_title>ACTHAR GEL Patients With Membranous ( Class V ) Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>Patients ≥ 18 year age pure Class V LN Class V+II LN diagnose kidney biopsy within 4 month screen . If patient segmental glomerular scar indicative previous Class III IV lesion , evidence current Class III IV activity , Class V component active , enrol , despite mandatory ISN/RPA classification Class V + III IV Proteinuria ≥ 3 g/d despite adequate blood pressure control define systolic blood pressure ≤ 130 mm Hg 75 % time , per clinical judgment site investigator . Serum creatinine &lt; 2 mg/dl eGFR &gt; 30 ml/minute Patients &lt; 18 year age Pregnancy planning become pregnant anytime throughout participation trial , 30 day last dose study drug . Kidney biopsy active Class III IV LN More 50 % interstitial fibrosis and/or glomerulosclerosis kidney biopsy Patients hepatitis B , C , HIV , TB active chronic infection time screen Patients liver disease transaminase great 2.5 time upper limit normal laboratory , patient diabetes mellitus type I II , patient refractory hypokalemia , patient Cushing 's Disease Syndrome Patients treat cyclophosphamide , cyclosporine A , tacrolimus , Bcell deplete therapy , experimental therapy include biologics within 6 month screen Patients active neuropsychiatric lupus , lupus pneumonitis , lupus vasculitis screen Patients high high extrarenal lupus activity define xSLEDAI score great 10 time screen Patients receive highdose intravenous methylprednisolone ( 1 g cumulative ) within 3 month screen Patients currently receive , receive MMF AZA 3 month precede enrollment extrarenal SLE . Patients receive methotrexate receive methotrexate discontinue eligible ; methotrexate stop safely , patient eligible . Patients currently receive 20 mg/d prednisone safely reduce 20mg/d less begin least one month enrollment day 0 Patients stable dose AntiMalarials and/or Antihypertensives least one month precede baseline visit study . ( Refer allow medication section )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>